Slide 1: Second Quarter 2024 Earnings
Second Quarter 2024 Earnings July 29, 2024
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Transformation Performance Upside driven by Software First anniversary of Revvity and Diagnostics offsetting Launched AP2400 workflow in May continued Pharma pressure for T-SPOT.TB latent TB diagnostic test to drive Commercial & Operational Strong expense management increase
Slide 4: 2Q24 Revenue Highlights
2Q24 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU RECURRING NON-RECURRING -DD +LSD +LSD $0.7 B -MSD -LSD $0.7 B +MSD $0.7 B -LSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our we
Slide 5: 2Q24 Financial Results
2Q24 Financial Results ADJUSTED REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $692M 28.7% $1.22 $160M -2% y/y -5bps y/y +1% y/y $293M YTD Organic: Adj. Gross Margin: Adj. Tax Rate: YTD FCF % Adj. NI -1% | M&A: 0% | FX: -1% 61.4% | -100bps y/y 21.1% 108% Adj. Net Interest & Other: Excludes A
Slide 6: Life Sciences
Life Sciences Product REVENUE AJUSTED OP MARGINS REAGENTS INSTRUMENTS SOFTWARE -6% Organic Growth 35.8% -LDD -220bps y/y Reported: -7% | M&A: 0% | FX: -1% $314 M • -MSD decline from both Pharma/Biotech and Academic/Gov’t customers -HSD 2Q24 revenue +DD • -Low-teens instruments decline; -HSD decline
Slide 7: Diagnostics
Diagnostics End Market REVENUE AJUSTED OP MARGINS IMMUNODX REPRODUCTIVE APPLIED HEALTH GENOMICS 3% Organic Growth 25.9% Reported: 1% | M&A: 0% | FX: -1% +300 bps y/y +LSD +HSD $378 M • +HSD ImmunoDX globally, China ImmunoDX flat 2Q24 revenue • +LSD Reproductive Health with +LSD newborn (+HSD ex. Chi
Slide 8: 2024 Financial Guidance
2024 Financial Guidance REVENUE $2.77B - $2.79B ~1% reported Organic: ~2% FX: -1%, M&A: 0% ADJUSTED OP. MARGIN 28.0-28.5% ADJUSTED EPS $4.70 - $4.80 Adj. Net interest expense, other: ~$50M Adjusted tax rate: ~20% Average diluted share count: 123.5M 8
Slide 9: Revvity.com
Revvity.com